Ciltacabtagene Autoleucel

A CAR-T cell therapy in which a patient's own T cells are genetically engineered to express chimeric antigen receptors targeting the BCMA protein on myeloma cells, used for relapsed or refractory multiple myeloma after multiple prior lines of therapy. Infusion of these modified cells can produce deep and durable remissions in heavily pretreated patients. Potentially serious adverse effects include cytokine release syndrome and neurotoxicity requiring specialized monitoring.

Yes, Ciltacabtagene Autoleucel is an approved drug. It has reached clinical phase 4. It is classified as a Gene.